Advanced in Squamous Cell Skin Carcinoma

Dr. Michael Gold

Dermatology
Gold Skin Care Center
2000 Richard Jones Rd Ste 220, 
Nashville, TN 
Advanced in Squamous Cell Skin Carcinoma
Gold Skin Care Center
2000 Richard Jones Rd Ste 220, 
Nashville, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Gold is a Dermatologist in Nashville, Tennessee. Dr. Gold is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Acne, Keloids, Athlete's Foot, and Melasma.

His clinical research consists of co-authoring 429 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Squamous Cell Skin Carcinoma.

Specialties
Dermatology
Licenses
Specialist in TN
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Gold Skin Care Center
2000 Richard Jones Rd Ste 220, Nashville, TN 37215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Feasibility Study to Evaluate Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler
A Feasibility Study to Evaluate Preliminary Safety and Effectiveness of SMI-01 as a Tissue Filler
Enrollment Status: Completed
Publish Date: May 31, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC)
Enrollment Status: Completed
Publish Date: March 18, 2024
Intervention Type: Drug, Other
Study Drug: STP705
Study Phase: Phase 2
A Pivotal USA Randomized, Evaluator-blinded, Active-controlled, Multi-center, Split-face Comparison Study of Emervel® Deep Lidocaine Versus Juvederm® Ultra Plus in the Treatment of Moderate to Severe Facial Wrinkles and Folds
A Pivotal USA Randomized, Evaluator-blinded, Active-controlled, Multi-center, Split-face Comparison Study of Emervel® Deep Lidocaine Versus Juvederm® Ultra Plus in the Treatment of Moderate to Severe Facial Wrinkles and Folds
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
Enrollment Status: Completed
Publish Date: March 14, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multi-Phase, Prospective, Multi-Center, Single-Blind, Clinical Study to Evaluate the Safety and Efficacy of Allograft Adipose Matrix (AAM) and Diluted AAM for Pre-Jowl and Malar Augmentation to Correct Age Related Volume Deficit in the Face
A Multi-Phase, Prospective, Multi-Center, Single-Blind, Clinical Study to Evaluate the Safety and Efficacy of Allograft Adipose Matrix (AAM) and Diluted AAM for Pre-Jowl and Malar Augmentation to Correct Age Related Volume Deficit in the Face
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Procedure
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra + (With Lidocaine) Versus Revanesse® Ultra for the Correction of Nasolabial Folds (NLF)
A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra + (With Lidocaine) Versus Revanesse® Ultra for the Correction of Nasolabial Folds (NLF)
Enrollment Status: Completed
Publish Date: April 11, 2019
Intervention Type: Device
Study Phase: Not Applicable
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat
Enrollment Status: Completed
Publish Date: October 20, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

429 Total Publications

GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities.
GLP-1 Receptor Agonists in Hidradenitis Suppurativa: A Novel Therapeutic Approach for Hidradenitis Suppurativa and Its Comorbidities.
Journal: Journal of drugs in dermatology : JDD
Published: December 02, 2025
Similar Doctors
Distinguished in Squamous Cell Skin Carcinoma
Dr. Sara Kantrow
Dermatology
Distinguished in Squamous Cell Skin Carcinoma
Dr. Sara Kantrow
Dermatology

Nashville Skin And Cancer PLC.

2301 21st Ave S, 
Nashville, TN 
 (1.7 miles away)
615-327-9797
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sara Kantrow is a Dermatologist in Nashville, Tennessee. Dr. Kantrow is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. Her top areas of expertise are Basal Cell Skin Cancer, Pustules, Sebaceous Adenoma, and Syringocystadenoma Papilliferum.

Distinguished in Squamous Cell Skin Carcinoma
Dr. Brent Moody
Dermatology
Distinguished in Squamous Cell Skin Carcinoma
Dr. Brent Moody
Dermatology

St. Thomas West Office - Dermatology

4230 Harding Pike, 
Nashville, TN 
 (2.6 miles away)
629-255-2124
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brent Moody is a Dermatologist in Nashville, Tennessee. Dr. Moody is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), and Bowen's Disease.

Distinguished in Squamous Cell Skin Carcinoma
Dr. Jerry Smith
Dermatology
Distinguished in Squamous Cell Skin Carcinoma
Dr. Jerry Smith
Dermatology

Belle Meade Dermatology PC

24 White Bridge Pike, 
Nashville, TN 
 (3.0 miles away)
615-352-0011
Languages Spoken:
English
See accepted insurances

Jerry Smith is a Dermatologist in Nashville, Tennessee. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Squamous Cell Skin Carcinoma. His top areas of expertise are Squamous Cell Skin Carcinoma, Basal Cell Skin Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), and Extramammary Paget Disease.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gold's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 50 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile